You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表现》诺辉健康(06606.HK)暗盘高开1.2倍报58.4元
阿思达克 02-17 16:16
根据辉立交易平台显示,明天挂牌的诺辉健康(06606.HK)暗盘高开1.2倍报58.4元获承接,现造79元,较上市价26.66元,飙1.96倍,成交18万股。

诺辉於2015年11月成立,是内地结直肠癌早期筛查市场先行者,根据弗若斯特沙利文,诺辉专有的非侵入性多靶点FIT-DNA 测试「常卫清」为内地首个兼唯一获国家药监局批准的分子癌症筛查测试。「常卫清」的目标客户为内地1.2亿结直肠癌高危人群,可让用户居家采集粪便样本,避免施行具有侵入性手术,同时取得较高测试灵敏度及特异性。

是次来港上市共发售7,659.8万股,并已引入包括景顺、清池资本、博裕及GIC等16名基石投资者,合共认购3,606.25万股;10%公开发售获4,132倍超购,启动回拨机制後占比增至50%,认购一手中签率仅2%,股份以招股范围(22.7-26.66元)上限定价,料集资净额约18.99亿元,主要用於为产品「常卫清」商业化和进一步开发提供资金、为正在进行与计划进行早期阶段管线产品研发提供资金、用作潜在收购或外部引进癌症筛查领域候选产品等。上市联席保荐人分别为高盛及瑞银。上市联席保荐人为高盛及瑞银。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account